Questions: Metaplasia and Dysplasia: Reversible and Irreversible Changes

Question 1

A patient with long-standing GERD develops Barrett's esophagus. After two years of aggressive acid-suppression therapy, follow-up endoscopy shows no Barrett's changes. What does this illustrate about metaplasia?

• A. The original diagnosis was incorrect — Barrett's cannot resolve once established
• B. Metaplasia is reversible when the chronic stressor driving it is removed
• C. The patient progressed to dysplasia, which appears different from metaplasia on biopsy
• D. Acid suppression converted metaplastic cells directly into normal squamous cells through targeted mutation repair

Answer: (B)

Reversibility is the defining characteristic of metaplasia. The metaplastic switch occurs because progenitor cells are reprogrammed toward a different differentiation pathway in response to chronic injury. Remove the injurious stimulus (gastric acid) and the progenitor cells can revert to producing the original cell type. This is fundamentally different from dysplasia, where accumulated genetic mutations cannot be reversed by removing the trigger — the genomic changes persist regardless of whether the irritant is controlled.

Question 2

A pathologist examining a biopsy reports 'nuclear pleomorphism, increased mitotic figures, and loss of normal tissue architecture.' Where does this finding fall on the metaplasia–dysplasia–carcinoma continuum?

• A. Metaplasia — these are features of a well-adapted alternative cell type responding to chronic stress
• B. Dysplasia — disordered growth reflecting accumulated mutations that uncouple cell division from normal regulation
• C. Carcinoma in situ — the cells have already undergone full malignant transformation
• D. Hyperplasia — more cells are being produced but they remain architecturally organized

Answer: (B)

Nuclear pleomorphism (variable nuclear size and shape), increased mitotic activity, and architectural disorganization are the histological hallmarks of dysplasia. Metaplastic cells, by contrast, are histologically normal — just a different cell type than expected. Hyperplasia involves more cells but preserves architecture. Carcinoma in situ involves invasive potential. Dysplasia is the intermediate stage where genetic instability is accumulating but invasive cancer has not yet developed.

Question 3

Metaplastic cells are histologically normal — they simply represent a cell type that is appropriate in a different anatomical location.

• T. True
• F. False

Answer: True

This is the crucial distinction between metaplasia and dysplasia. In metaplasia, progenitor cells are reprogrammed to produce a different differentiated cell type, but that type is perfectly normal — the intestinal columnar epithelium in Barrett's esophagus is the same cell found in the small intestine. The cells are architecturally organized and appear normal under the microscope. The pathological concern arises from the mismatch between cell type and location, and from the potential for progression, not from the cells themselves being intrinsically abnormal.

Question 4

Dysplasia is best understood as an advanced form of metaplasia in which the alternative cell type becomes more pronounced.

• T. True
• F. False

Answer: False

Dysplasia is not 'more metaplasia' — it represents a qualitatively different process. Metaplasia involves progenitor cell reprogramming toward a different but still normal differentiation pathway, with normal cell division and architecture preserved. Dysplasia involves accumulation of genetic mutations (in tumor suppressors like TP53, DNA repair genes, or cell cycle regulators) that begin to uncouple cell proliferation from normal regulatory controls. Dysplastic cells are not simply an extreme alternative cell type; they are cells with genomic instability — disordered nuclei, abnormal mitoses, and architectural chaos.

Question 5

Why does dysplasia carry greater malignant potential than metaplasia, even though both arise in response to chronic tissue irritation?

Model answer: Metaplasia is a programmed adaptive response — progenitor cells shift to a different but still normal differentiation pathway with intact regulatory machinery. The cell division controls, architectural organization, and DNA repair systems remain functional. Dysplasia, by contrast, reflects accumulated genetic mutations in tumor suppressors, DNA repair pathways, or cell cycle regulators that begin to uncouple cell proliferation from normal controls. Each additional mutation increases cellular autonomy and raises the probability that the next mutation will drive further toward malignancy. Dysplastic cells carry heritable genomic instability that cannot be reversed by removing the inciting stimulus — which is exactly why the clinical response escalates from surveillance (metaplasia) to active intervention (high-grade dysplasia).

The reversibility difference follows directly: metaplasia reverts because progenitor cell machinery is intact; dysplasia cannot revert because the mutations are already in the cell's DNA. This molecular logic underlies the entire clinical management continuum.